Dental Implants With a Platform-Switched Morse Taper Connection and an Osteo Growth Induction Surface

Aim: The aim of this study was to analyze the clinical outcomes after using an innovative implant system characterized by a modern platform-switched Morse taper connection and an osteo growth induction titanium surface (a particular type of SLA surface). Peri-implant bone loss (PBL) and implant success rate were examined after a 1- to 3-year follow-up. Methods: The study was conducted as a cross-sectional analysis on all patients treated from January 2011 to December 2014 using CLC CONIC implants. Implants were divided into 3 main groups, based on the duration of the follow-up (1 year, 2 years, and 3 years), then subgrouped by diameter, length, and type of prosthetic rehabilitation to compare differences in PBL. X-rays were taken at the time of surgery, at prosthetic loading, at 1 year, and then annually thereafter. Previously-established success criteria were used to assess the implants. Frequency analyses and comparisons between the means (with 95% CI) were conducted for the statistical analysis of the data collected. Results: One hundred twenty patients met inclusion and exclusion criteria, and completed the follow-up, and were thus eligible for the study, with a total of 261 CLC CONIC implants. The mean follow-up was 22.45 months. No implants failed, giving an overall success rate of 100%. The average PBL at 1-year follow-up was 0.047 mm, at 2 years it was 0.128 mm, and at 3 years it was 0.236 mm. Conclusions: The CLC CONIC implant system had a high success rate after 1 to 3 years of follow-up, in line with previous reports in the scientific literature. Combining platform switching with the Morse taper connection enabled stable bone levels to be achieved in the short to medium term. Address correspondence and reprint requests to Paolo Ghensi, DDS, Clin Msc, via Chini 101/2, 38123 Trento (TN), Italy; E-mail: dr.ghensi@gmail.com Received 29 April, 2018 Accepted 23 May, 2018 Claudio Soldini declares a conflict of interest with the implant brand used in this clinical study as co-owner of the company CLC Scientific. The remaining authors report no conflicts of interest. © 2018 by Mutaz B. Habal, MD.

https://ift.tt/2OotWTP